Benzinga | Jan 11, 2021 05:02AM EST

Dr. Reddy's Laboratories Launched Febuxostat Tablets in U.S. Market

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets approved by the U.S. Food and Drug Administration (USFDA).

The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health*.

Dr. Reddy's Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.

Please see the full prescribing information including boxed warning.

https://www.drreddys.com/pi/febuxostat_tablets.pdf